Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
The APDN news archive on Stock Titan covers the historical disclosures and announcements of Applied DNA Sciences, Inc., a biotechnology company that developed and commercialized polymerase chain reaction (PCR)-based technologies for DNA production and detection and later adopted a BNB-focused digital asset treasury strategy. During the period when it traded under the Nasdaq symbol APDN, the company issued news on operational restructuring, platform development, customer activity, and capital markets transactions.
Readers can review company updates describing the transition to a pure play provider of synthetic DNA and mRNA manufacturing solutions through its majority-owned subsidiary LineaRx, Inc., including the focus on its LineaDNA, LineaRNAP, and LineaIVT platforms. News items detail workforce reductions, the exit from DNA tagging and security products and services, the closure of Applied DNA Clinical Labs, and the consolidation of operations behind LineaRx to support advanced biotherapeutics and diagnostic applications.
The archive also includes announcements related to conference participation and scientific posters showcasing the LineaDNA and LineaIVT platforms, follow-on orders for LineaDNA from a global in vitro diagnostics manufacturer for use in a cancer diagnostic application, and engagements with mRNA-focused contract development and manufacturing organizations. Financial news covers quarterly results, non-GAAP metrics such as Adjusted EBITDA and monthly net cash burn, and commentary on cost optimization and capital allocation.
Later APDN news releases document the company’s initiation of a BNB-focused digital asset treasury strategy, private placement commitments to fund BNB acquisitions, and the planned change of its Nasdaq ticker from APDN to BNBX to reflect this strategic focus. These items describe agreements with Cypress LLC and Cypress Management LLC for digital asset management and advisory services, as well as the involvement of institutional and crypto-native investors. By following this archive, investors can trace how APDN evolved from a biotechnology-focused issuer into BNB Plus Corp. (BNBX) with a combined profile in nucleic acid production and digital asset treasury management.
Applied DNA Sciences (NASDAQ: APDN) announced $1.6 million in purchase orders from a textile customer for molecular taggant to tag textile fibers. Most shipments are expected by September 30, 2021. The company is also progressing textile projects with major apparel brands, which could open new commercial opportunities in fiscal 2022. The CertainT® traceability platform supports supply chain transparency from fiber to finished goods, increasingly in demand post-pandemic.
Applied DNA Sciences, Inc. (NASDAQ: APDN) has enhanced its partnership with TruTrace Technologies to support the StrainSecure 2.0 platform, aimed at improving cannabis product validation and supply chain transparency. This integration follows their strategic alliance launched in January 2021. StrainSecure 2.0 will help cannabis companies meet growing regulations and provide enhanced product authenticity. Key features include a shared ledger for tracking cannabis products and a marketing tool for real-time product data. This collaboration seeks to mitigate risks and ensure compliance in the evolving cannabis industry.
Applied DNA Sciences (NASDAQ: APDN) has signed a Master Services Agreement with Flora Growth (NASDAQ: FLGC) to integrate its CertainT® platform for cannabis product validation and authentication. The company will implement this technology across three locations (1 in Florida, 2 in Colombia) to enhance supply chain transparency and product trust. The CertainT platform, which includes molecular tagging, aims to support Flora's global distribution strategy and compliance with pharmaceutical standards as they expand in international markets like Australia. Financial details were not disclosed.
Applied DNA Sciences (NASDAQ: APDN) announced that Dr. James A. Hayward, president and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The virtual presentation will be available on September 13, 2021, at 7:00 am (EST) via the Company's website. Applied DNA is known for its LinearDNA platform, which aids in large-scale DNA production for various applications, including diagnostics and drug development. The company also offers safeCircle, a pooled COVID-19 testing program.
Applied DNA Sciences (NASDAQ: APDN) announced a contract with Suffolk County Community College to implement its safeCircle™ COVID-19 testing program among unvaccinated staff and faculty. The contract, starting in late September 2021, allows for a one-year term with two optional renewals. ADCL will utilize its Linea™ COVID-19 Assay Kit for testing, enhancing virus mitigation strategies on campus. The safeCircle program is designed for high-throughput, pooled testing and is aligned with SUNY's vaccination mandate.
Applied DNA Sciences reported a 294% revenue growth in Q3 2021, reaching $1.7 million, driven by their safeCircle COVID-19 testing program and product sales, particularly the Linea Assay Kit. However, revenues decreased by 36% from the previous quarter. Total operating expenses rose to $4.5 million, leading to a net loss of $3.5 million or $0.46 per share. The company is optimistic about a new COVID-19 testing services contract and the potential EUA for their Linea Mutation Panel. Cash reserves improved to $12.2 million.
Applied DNA Sciences (NASDAQ: APDN) announced it will release its fiscal 2021 third quarter financial results on August 12, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. EDT, where the management team will discuss the results. Participants may access the conference via dial-in numbers provided in the announcement, with a replay available for one week post-call. The company focuses on PCR-based DNA manufacturing and nucleic acid technologies, with applications in diagnostics and drug development.
Applied DNA Sciences (NASDAQ: APDN) announced a COVID-19 testing contract with the City University of New York (CUNY) valued at up to $35 million over 12 months. Its subsidiary, Applied DNA Clinical Labs, will implement the safeCircle™ testing program for weekly asymptomatic screening of students, staff, and faculty. Testing, projected at 20,000 to 65,000 weekly, starts in August 2021, enhancing safety before in-person classes resume. The company is also set to report Q3 financial results on August 12, 2021.
Applied DNA Sciences, Inc. (NASDAQ: APDN) and American & Efird (A&E) have announced the launch of A&E's INTEGRITY™ ECO100, a sustainable and secure sewing thread that integrates Applied DNA's CertainT® technology. This innovative product is made from 100% recycled fibers and allows brands to authenticate and validate their products throughout the supply chain. Celebrity designer Sara Caverley will utilize this thread in her footwear line, enhancing supply chain security. The collaboration aims to address the growing concerns of counterfeiting and ensure sustainability within the textile industry.
Applied DNA Sciences (NASDAQ: APDN) and Evvivax announced results from a study involving 11 vaccinated felines with their LinearDNA™ COVID-19 vaccine candidate. The study indicated neutralizing antibody production against SARS-CoV-2 variants B.1.1.7, P1, and B.1.526. While titers against B.1.1.7 showed no significant impact, reductions against P1 and B.1.526 were consistent with CDC data. The Company remains optimistic about the vaccine's effectiveness. A trial with mink is set to begin in August to further assess the vaccine's protective capabilities.